[go: up one dir, main page]

SG11201505737YA - Use of phenoxypropylamine compounds to treat depression - Google Patents

Use of phenoxypropylamine compounds to treat depression

Info

Publication number
SG11201505737YA
SG11201505737YA SG11201505737YA SG11201505737YA SG11201505737YA SG 11201505737Y A SG11201505737Y A SG 11201505737YA SG 11201505737Y A SG11201505737Y A SG 11201505737YA SG 11201505737Y A SG11201505737Y A SG 11201505737YA SG 11201505737Y A SG11201505737Y A SG 11201505737YA
Authority
SG
Singapore
Prior art keywords
treat depression
phenoxypropylamine compounds
phenoxypropylamine
compounds
depression
Prior art date
Application number
SG11201505737YA
Inventor
Lorenzo Pellegrini
Argeris Karabelas
Remy Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of SG11201505737YA publication Critical patent/SG11201505737YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201505737YA 2013-01-24 2014-01-24 Use of phenoxypropylamine compounds to treat depression SG11201505737YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361756208P 2013-01-24 2013-01-24
US201361852149P 2013-03-15 2013-03-15
US201361799482P 2013-03-15 2013-03-15
PCT/US2014/013026 WO2014117003A1 (en) 2013-01-24 2014-01-24 Use of phenoxypropylamine compounds to treat depression

Publications (1)

Publication Number Publication Date
SG11201505737YA true SG11201505737YA (en) 2015-08-28

Family

ID=51208168

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505737YA SG11201505737YA (en) 2013-01-24 2014-01-24 Use of phenoxypropylamine compounds to treat depression
SG10201706035QA SG10201706035QA (en) 2013-01-24 2014-01-24 Use of phenoxypropylamine compounds to treat depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201706035QA SG10201706035QA (en) 2013-01-24 2014-01-24 Use of phenoxypropylamine compounds to treat depression

Country Status (23)

Country Link
US (3) US20140206722A1 (en)
EP (2) EP2948143B1 (en)
JP (2) JP6422890B2 (en)
KR (4) KR20210047368A (en)
CN (2) CN110664813A (en)
AU (4) AU2014209200B2 (en)
BR (1) BR112015017628A2 (en)
CA (2) CA3150231A1 (en)
CL (1) CL2015002069A1 (en)
DK (1) DK2948143T3 (en)
ES (1) ES2875058T3 (en)
IL (4) IL287727B2 (en)
MX (2) MX2015009445A (en)
MY (1) MY185908A (en)
NZ (2) NZ750189A (en)
PE (1) PE20151888A1 (en)
PH (1) PH12015501643B1 (en)
PL (1) PL2948143T3 (en)
PT (1) PT2948143T (en)
RU (2) RU2725112C2 (en)
SG (2) SG11201505737YA (en)
WO (1) WO2014117003A1 (en)
ZA (2) ZA201505114B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848641A (en) * 2016-05-25 2022-08-05 田边三菱制药株式会社 Compounds or metabolites thereof for use in the treatment of anxiety disorders
WO2019070939A1 (en) * 2017-10-04 2019-04-11 NeuroGeneces LLC Sleep performance system and method of use
JP7439096B2 (en) 2018-09-04 2024-02-27 田辺三菱製薬株式会社 Methods of using phenoxypropylamine compounds to treat pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
EA004704B1 (en) 1999-05-24 2004-06-24 Мицубиси Фарма Корпорейшн Phenoxypropylamine derivatives
DE60010758T2 (en) * 1999-12-20 2005-05-12 Eli Lilly And Co., Indianapolis Piperidine derivatives and their use as serotonin receptor antagonists
RU2424799C1 (en) * 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Method of correcting depressive disorders by thietan-1,1-dioxide derivatives in experiment

Also Published As

Publication number Publication date
US20200223838A1 (en) 2020-07-16
AU2014209200B2 (en) 2018-11-01
BR112015017628A2 (en) 2017-07-11
AU2019200512B2 (en) 2020-04-16
DK2948143T3 (en) 2021-07-26
EP2948143A1 (en) 2015-12-02
NZ750189A (en) 2020-08-28
KR20210047368A (en) 2021-04-29
ZA202207530B (en) 2023-10-25
PH12015501643A1 (en) 2015-10-12
CA2898279A1 (en) 2014-07-31
MX2015009445A (en) 2016-01-14
CL2015002069A1 (en) 2016-05-20
EP2948143B1 (en) 2021-05-05
IL239928A0 (en) 2015-08-31
WO2014117003A1 (en) 2014-07-31
EP2948143A4 (en) 2017-02-22
MY185908A (en) 2021-06-14
IL278109A (en) 2020-11-30
RU2725112C2 (en) 2020-06-29
AU2022241458A1 (en) 2022-10-20
RU2020120236A (en) 2020-09-01
KR20200086377A (en) 2020-07-16
ZA201505114B (en) 2023-09-27
IL239928B (en) 2021-04-29
JP2018172400A (en) 2018-11-08
AU2019200512A1 (en) 2019-02-14
RU2015135358A (en) 2017-03-03
JP2016510331A (en) 2016-04-07
PT2948143T (en) 2021-06-03
KR102172351B1 (en) 2020-11-02
EP3925608A3 (en) 2022-01-19
KR102587177B1 (en) 2023-10-06
PH12015501643B1 (en) 2015-10-12
CA2898279C (en) 2022-05-17
IL287727B2 (en) 2024-08-01
PE20151888A1 (en) 2016-01-13
KR20150120987A (en) 2015-10-28
US20250109127A1 (en) 2025-04-03
AU2014209200A1 (en) 2015-07-30
NZ709967A (en) 2020-05-29
ES2875058T3 (en) 2021-11-08
EP3925608A2 (en) 2021-12-22
AU2020205268A1 (en) 2020-08-06
IL287727A (en) 2021-12-01
PL2948143T3 (en) 2021-12-13
JP6657315B2 (en) 2020-03-04
AU2020205268B2 (en) 2022-07-07
CA3150231A1 (en) 2014-07-31
CN105377255A (en) 2016-03-02
KR102247960B1 (en) 2021-05-07
MX388354B (en) 2025-03-19
AU2022241458B2 (en) 2024-11-14
KR20220112865A (en) 2022-08-11
IL311363A (en) 2024-05-01
JP6422890B2 (en) 2018-11-14
IL278109B (en) 2022-03-01
US20140206722A1 (en) 2014-07-24
IL287727B1 (en) 2024-04-01
CN110664813A (en) 2020-01-10
SG10201706035QA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IL287516A (en) Therapeutic uses of empagliflozin
IL241101B (en) Therapeutic uses of empagliflozin
SG11201507121RA (en) Treatment of cataplexy
RS63939B1 (en) Inhibitors of lysine specific demethylase-1
IL241102A0 (en) Therapeutic uses of empagliflozin
SI2981271T1 (en) Therapeutic uses of empagliflozin
EP2958964A4 (en) Treatment of frequently touched surfaces to improve hygiene
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
ZA201602831B (en) Use of lactones
IL240763A0 (en) Halogenopyrazoles as inhibitors of therombin
ZA201505048B (en) Composition of tiacumicin compounds
IL244035A0 (en) Treatment of gases
GB2525530B (en) Treatment of hard surfaces
GB201314303D0 (en) Treatment of HPV